BioSapien Extends Pre-Series A to Over $8M with Globivest's Support
Deal News | Jul 07, 2025 | Zawya
BioSapien, a leading biotech company, announces an extension to its pre-Series A funding round, bringing its total to over $8 million. This funding includes new investment from Globivest, the first women-led venture capital fund in the MENA region, known for its expertise in Life Sciences. This strategic funding round positions BioSapien on the path to revolutionize localized cancer treatment through its MediChip platform, designed to deliver targeted and sustained therapeutic release directly to tumor sites. Additionally, BioSapien has strengthened its team by appointing high-caliber professionals across various sectors, enhancing its technological, operational, and medical expertise. The company, headquartered in both the U.S. and UAE, aims to bolster the UAE's vision in advancing precision medicine and localized healthcare innovation. BioSapien's partnership with Globivest is seen as a strategic alignment in advancing biotech initiatives on a global scale, particularly in precision medicine.
Sectors
- Biotechnology
- Venture Capital
- Healthcare
Geography
- United Arab Emirates – BioSapien has headquarters in the UAE and is contributing to its burgeoning biotech ecosystem.
- United States – BioSapien is headquartered in the U.S., reflecting its international operational base.
- MENA Region – Globivest operates from the MENA region and its involvement underscores the geographical breadth of the investment.
Industry
- Biotechnology – BioSapien operates within the biotechnology sector, focusing on developing innovative localized cancer treatment solutions.
- Venture Capital – Globivest, along with other investors, is involved in providing crucial funding for BioSapien, highlighting its role within the venture capital sector.
- Healthcare – The article discusses advancements and strategic growth in precision medicine, placing it squarely within the healthcare industry.
Financials
- Over $8 million – The total amount accumulated in the pre-Series A funding round for BioSapien.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| BioSapien | Target Company | Company | A biotech company focused on developing localized drug delivery systems for cancer treatment. |
| Globivest | Investor | Company | A women-led venture capital fund from the MENA region specializing in impactful investments in early-stage life sciences startups. |
| Global Ventures | Investor | Company | A leading VC firm in the MENA region also investing in BioSapien. |
| Golden Gate Ventures | Investor | Company | Another participating investor providing capital to BioSapien. |
| Dara Holdings | Investor | Company | Investor participating in BioSapien's funding round. |
| Joseph Borrello PhD | Chief Technology Officer | Person | Appointed as BioSapien's new CTO to enhance technology initiatives. |
| Sonia Ramamoorthy MD MBA FACS | Head of Medical Affairs | Person | New head of Medical Affairs joining BioSapien to strengthen medical strategy. |
| Agnes Westelinck PharmD | Head of Regulatory U.S. | Person | Responsible for regulatory affairs in the U.S. for BioSapien. |
| Dirk Richter MD FACS | Head of Regulatory U.A.E. | Person | In charge of regulatory strategy in the UAE for BioSapien. |
| David Briere PhD | Director of Pharmacology | Person | Joining BioSapien to advance pharmacological research. |
| Jerry Webb BSc | Head of Quality | Person | New head of Quality at BioSapien, overseeing compliance and standards. |
| Dr. Khatija Ali | CEO of BioSapien | Person | CEO offering strategic direction and leadership at BioSapien. |
| Dr. Laura-Joy Boulos | Partner at Globivest | Person | Partner at Globivest and proponent of its One Health approach. |